drugset / Trial / NCT04069234
Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention.
Phase 3
Withdrawn
Region Skane
AstraZeneca · collabHippocrates Research · collabIHF GmbH - Institut für Herzinfarktforschung · collabIRW consulting AB · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This study is designed to test the hypothesis that ticagrelor is superior to clopidogrel, in improving coronary microvascular function, as measured by coronary flow reserve (CFR) in patients with T2DM at high risk of cardiovascular (CV) events undergoing elective PCI.
Timeline
- Start
- 2019-09-15
- Primary completion
- 2021-10-15
- Completion
- 2022-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Clopidogrel | Small molecule | 75 mg | — |
| Subject | Ticagrelor | Small molecule | 60 mg | — |